ARCH THERAPEUTICS, INC. OMNIBUS AMENDMENT TO NOTES AND WARRANTSNotes and Warrants • August 11th, 2023 • Arch Therapeutics, Inc. • Surgical & medical instruments & apparatus
This Omnibus Amendment to Notes and Warrants (this “Amendment”) to those certain (i) “First Notes” (the “First Notes”) (as defined in the Purchase Agreement (as defined below)), (ii) “Second Notes” (the “Second Notes”) (as defined in the Purchase Agreement), (iii) Third Notes (the “Third Notes” and, collectively with the First Notes and Second Notes, the “Notes”) (as defined in the Purchase Agreement), and (iv) related warrants (the “First Warrants”, “Second Warrants” and “Third Warrants”, respectively, and collectively, the “Warrants”) issued pursuant to the certain Securities Purchase Agreement, dated July 6, 2022, as amended on January 18, 2023 and May 15, 2023 (as amended, the “Purchase Agreement”), by and among Arch Therapeutics, Inc., a Nevada corporation (the “Company”) and certain institutional and accredited institutional investors (collectively, the “Holders”), is made by and among the Company and the Consenting Stockholders (as defined below). Capitalized terms not otherwise
AMENDMENT TO SECURED CONVERTIBLE PROMISSORY NOTES AND WARRANTSNotes and Warrants • February 3rd, 2010 • Huifeng Bio-Pharmaceutical Technology, Inc. • Medicinal chemicals & botanical products
This Amendment to Secured Convertible Promissory Notes and Warrants (this “Agreement”) is entered into by and between Huifeng Bio-Pharmaceutical Technology, Inc., a Nevada Corporation (the “Company), and each of those persons and entities, severally and not jointly, whose names are set forth on the Schedule of Lenders attached hereto as Exhibit A (which persons and entities are hereinafter collectively referred to as “Lenders” and each individually as a “Lender”) on the 24th day of December, 2009 (the “Effective Date”), amending certain provisions of those certain Secured Convertible Promissory Notes dated December 31, 2007 (each, a “Note” and together, the “Notes”) and those certain Warrants dated December 31, 2007 (each a “Warrant” and together, the “Warrants”). All capitalized terms used, but not defined herein, shall have the meanings given to them in the Notes.
AMENDMENT TO NOTES AND WARRANTSNotes and Warrants • March 16th, 2017 • Agenus Inc • Biological products, (no disgnostic substances) • New York
This Amendment to Notes and Warrants (this “Amendment”) is entered into this 15th day of March, 2017 by and between (a) Agenus Inc., a Delaware corporation, having an address at 3 Forbes Road, Lexington, MA 02421 (the “Company”), and (b) Mark Berg, Nicole Berg, Alice Saraydarian and Khajak Keledjian (collectively, the “Original Investors”) and (c) Nicky V LLC and MSB Research Inc. (together, the “Additional Investors” and collectively with the Original Investors, the “Investors”).
AMENDMENTS TO CERTAIN AVAX AGREEMENTS, NOTES AND WARRANTSNotes and Warrants • February 4th, 2011 • Avax Technologies Inc • Biological products, (no disgnostic substances) • Delaware
These Amendments (the “Amendments”) to certain Agreements, Notes and Warrants (collectively, the “Agreements”) are entered into effective as of October 28, 2010, by and between AVAX Technologies, Inc., a Delaware corporation (the “Company”), and Firebird Global Master Fund, Ltd., (the “Purchaser”). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in the respective Agreements.
Agreement to Amend Notes and WarrantsNotes and Warrants • July 28th, 2010 • Daystar Technologies Inc • Semiconductors & related devices • New York
This Agreement to Amend Notes and Warrants (this “Agreement”) is made as of July 22, 2010, by and between DayStar Technologies, Inc., a Delaware corporation (the “Company”), and (the “Holder”).
